الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Appropriate early intervention in patients with ACS can save lives. This survival benefits, however, is time-dependent, and steadily declines in the hours that follow the first signs of ischemic injury. This is the famous time is muscle axiom that drives the early management of ACS. ACS is generally classified into three coronary arteriesrelated conditions: ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina (UA). Worse prognostic information of ACS can be obtained from routine hematologic tests such as CBC through the important role of blood elements of the pathogenesis of ACS. Lectin-like oxidized LDL receptor-1 (LOX-1) may be more useful for diagnosing ACS at the earliest stage (LOX-1) appears to play crucial roles in the pathogenesis of atherosclerotic plaque rupture and ACS onset. LOX-1 is released in part as soluble LOX-1 (sLOX-1) by proteolytic cleavage, it has a very important role in the diagnosis accuracy of acute coronary syndromes or to predict disease progression or the risk of future cardiovascular events. Aims: The aim of this work is to discuss acute coronary syndrome in intensive care unit, as well as, the hematological changes, Role of lectin like Oxidized LDL-1 Receptor and recent biomarkers in diagnosis and prognosis of this problem. Conclusion: Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. Accordingly, early and accurate diagnosis of acute coronary syndrome (ACS) is a critical step for improving patient health outcomes. Lectin-like oxidized LDL receptor-1 (LOX-1) may be more useful for diagnosing ACS at the earliest stage. |